Novartis plans strategy to offset high cost of new heart failure drug
Novartis CEO Joe Jimenez told the Wall Street Journal that the company is considering offering add-on healthcare services to insurers concerned with the high costs of its newest drug.
On July 7, the FDA approved sacubitril/valsartan (Entresto), a twice-daily oral medication to treat patients with heart failure and reduced ejection fraction. At $12.50 per patient per day, the medication costs much more than older drugs, which cost less than a dollar per dose. Read more at the link below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.